Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
NCT06422351Phase 2Suspended
- Sponsor
- Rocket Pharmaceuticals, Inc.
- Start
- Apr 2026
- Primary completion
- Jan 2029
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of RP-L301 in pyruvate kinase deficiency (PKD), sponsored by Rocket Pharmaceuticals, Inc. Primary endpoint: Improvement in Anemia at 12 months. Started Apr 2026; status: suspended.
02
Drugs
RP-L301
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on NCT06422351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422351.